Director and Faculty Profiles

Barbara E. Murray, MD
DIRECTOR
Professor of Medicine
Director, Division of Infectious Diseases
Director, Center for the Study of Emerging and Re-emerging Pathogens

Barbara E. Murray, MD is a 1969 cum laude graduate in mathematics from Rice University in Houston, Texas, and graduated first in her class (Ho Din Award and AOA) from the University of Texas Southwestern Medical School in Dallas in 1973.  She then spent 6 years training in Internal Medicine and Infectious Diseases at Harvard Medical School’s Massachusetts General Hospital, in Boston, followed by 6 months in Thailand conducting research at the Armed Forces Research Institute of Medical Sciences.  She joined the faculty at the University of Texas-Houston Medical School as an assistant professor in 1980, rising through the ranks to Professor by 1990, became Director of the Division of Infectious Diseases in 1995, and the J. Ralph Meadows Professor in 2003.  She is also co-director of the UTHSC-H Center for the Study of Emerging and Re-Emerging Pathogens.

Dr. Murray is a nationally and internationally recognized expert in infectious diseases, microbiology and bacterial pathogenesis, conducts NIH funded research (including a current MERIT award), has served on a number of NIH committees and study sections, including as past Chair of the NIH Recombinant DNA Advisory Committee, as well as on the FDA’s Anti-Infectives Advisory Committee; she has also served on a number of Advisory Boards as a consultant to the pharmaceutical industry. She is past chair (3 year term) of the Program Planning Committee of the American Society of Microbiology’s ICAAC meeting, the world’s largest infectious diseases meeting; she served a 10-year term as an editor of Antimicrobial Agents and Chemotherapy, a journal published by the American Society of Microbiology; she currently serves on the Program Committee of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and is a frequent visiting professor at other medical schools and a frequent invited speaker at national and international meetings.  Dr. Murray is an active member of the Infectious Diseases Society of America and is its Secretary-Treasurer.

Dr. Murray’s laboratory's broad interests involve the genetic and biochemical mechanisms of resistance to antibiotics and bacterial pathogenicity, particularly relating to enterococci, and molecular epidemiologic typing methods.  Recent acquisition of antibiotic resistance traits have led enterococci to be called antibiotic resistant "super bugs" because of the lack of commercially available effective antibiotics.  Work in her laboratory has included the first description of enterococci producing beta-lactamase, the first enterococci with high level resistance to all aminoglycosides, and the first enterococcal gentamicin resistance transposon.  Work in pathogenicity, funded by two NIH grants, has been directed towards defining the enterococcal factors that contribute to infection, generation of isogenic mutants for studies of virulence, testing the potential protective effect of antiserum, identification of gene(s) encoding adherence to extracellular matrix proteins and characterization of a polysaccharide biosynthesis gene cluster of E. faecalis her group recently identified.  Her recent description of E. faecalis pili (published in the Journal of Clinical Investigation) showed the importance of these structures to biofilm formation and experimental endocarditis and, subsequently, their importance in experimental urinary tract infection.  There are active collaborations between her laboratory and the faculty in the Department of Microbiology and Molecular Genetics, the Center for Matrix Biology of TAMU, and the Human Genome Sequencing Center at BCM.  Her research has resulted in over 200 papers in peer reviewed journals, as well as a number of reviews, chapters, and invited articles.

Peer reviewed publications since 2003:

Professional Organizations:
• American Society for Microbiology
• American Federation for Clinical Research
• Infectious Diseases Society of America, Fellow
• International Society for Infectious Diseases
• American Society for Clinical Investigation
• The Association of American Physicians
• National Foundation of Infectious Diseases, Board of Directors

Roberto C. Arduino, MD
Professor of Medicine
UT Director of Clinical Research, Thomas Street Clinic

Roberto C Arduino, MD graduated from Universidad de Buenos Aires Medical School in 1982, trained in internal medicine from 1982 through 1987, and completed his fellowship in infectious diseases in 1989 in Buenos Aires. He did additional infectious diseases training at the University of Texas Medical School at Houston from 1990-1994. He has been actively involved in well funded HIV research, first in his native Argentina and now as a Professor in the Division of Infectious Diseases at the University of Texas Medical School at Houston. His current research includes clinical studies in new antiretroviral drugs, treatment strategies, immunomodulators, and research on lymphocyte subpopulations and viral and host genetics. Dr. Arduino is the PISite Leader for the NIH funded CPCRA (Community Program for Clinical Research on AIDS) Clinical Research sSite Houston AIDS Research Team for the AIDS Clinical Trial Group (ATCG) network and the principal investigator for the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).

Peer reviewed publications since 2000:

• Rakita RM, Quan VC, Jacques-Palaz K, Singh KV, Arduino RC, Mee M, and Murray BE. Specific antibody promotes opsonization and PMN-mediated killing of phagocytosis-resistant Enterococcus faecium. FEMS Immunol Med Microbiol 2000;28:291-299.
• Nannini EC, Han X, O'Brien WA, Arduino RC. Genotypic HIV-1 Drug Resistance Testing in Antiretroviral-Naive Subjects in Houston, Texas. J Acquir Immune Defic Syndr 2002;29:317-319.
• Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, Neaton JD; ESPRIT Study Group. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002;23:198-220.
• Kilby MJ, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR, and Dusek A. The safety, plasma pharmacokinetics and antiviral activity of subcutaneous T 20, a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002;18:685-693.
• Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, Gallant JE, Volberding P, Murphy RL, Valentine F, Nelson EL, Sista PR, Dusek A and Kilby JM. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003;17:691-698.
• Giordano TP, White Jr AC, Sajja P, Graviss EA, Arduino RC, Adu-Oppong A, Lahart CJ, Visnegarwala F. Factors Associated with the Use of Highly Active Antiretroviral Therapy in Patients Newly Entering Care in an Urban Clinic. J Acquir Immune Defic Syndr 2003;32:399-405.
• Tedaldi EM, Hullsiek KH, Malvestutto CD, Arduino RC, Fisher EJ, Gaglio PJ, Jenny-Avital ER, McGowan JP, Perez G, for the Terry Beirn Community Programs for Clinical Research on AIDS. Prevalence and Characteristics of HCV Coinfection in a Human Immunodeficiency Virus Clinical Trials Group: The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 2003;36:1313-1317.
• Vidrine DJ, Amick BC, 3rd, Gritz ER, Arduino RC. Functional Status and Overall Quality of Life in a Multiethnic HIV-Positive Population. AIDS Patient Care STDs 2003;17:187-197.
• Lepetic A, Biscayart C, Seigelchifer M, Arduino R, Stamboulian D. Persistence of immunity and seroprotection four years after a primary vaccination schedule with a Hansenula polymorpha recombinant hepatitis B vaccine. Vaccine 2003;21:4481-4485.
• Vidrine DJ, Amick BC, 3rd, Gritz ER, Arduino RC. Validity of the Household and Leisure Time Activities Questionnaire (HLTA) in a multiethnic HIV-positive population. AIDS Care 2004;16:187-197.
• Gritz ER, Vidrine DJ, Lazev AB, Amick BC, 3rd, and Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res 2004;6:71-77.
• Lazev AB, Vidrine DJ, Arduino RC, Gritz ER. Increasing access to smoking cessation treatment in a low-income HIV-positive population: The feasibility of using cellular telephones. Nicotine Tob Res 2004;6:281-286.
• Arduino RC, Nannini EC, Rodrigues-Barradas M, Schrader S, Losso M, Ruxrungtham K, Allende M, Emery S, Fosdick L, Neaton J, Tavel J, Davey R, Lane HC. CD4 Cell Response to Three Doses of Subcutaneous Interleukin-2: Meta-analysis of Three Vanguard Studies. Clin Infect Dis 2004;39:115-122.
• Eron JJ, Gulick RM, Bartlett J, Merigan T, Arduino RC, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD. Short-Term Safety and Antiretroviral Activity of T-1249, a Second Generation Fusion Inhibitor of HIV. J Infect Dis 2004;189:1075-1083.
• Vidrine DJ, Amick BC, 3rd, Gritz ER, Arduino RC. Assessing a proximal-distal model of quality of life in an HIV-positive population. Qual Life Res 2005; 14:923-933.
• Arduino, RC. CD4 cell count-guided treatment interruption: be smart and wait for more evidence. Clin Infect Dis 2005;40(5):735-7.
• Vidrine DJ, Arduino RC, Lazev AB, Gritz ER. A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/AIDS. AIDS 2006; 20(2):253-60.
• Lee S, Arora R, Bull LM, Arduino RC, Garza L, Allan JS, Kimata JT, and Zhou P. A non-neutralizing anti-HIV-1 antibody turns into a broad neutralizing antibody when expressed on the surface of HIV-1-susceptible cells (II): inhibition of HIV-1 captured and transferred by DC-SIGN. AIDS Res Human Retroviruses (In press).
• Pett SL, Wand H, Law MG, Arduino R, Lopez JC, Knysz B, Pereira LC, Pollack S, Reiss P, Tambussi G, ESPRIT Research Group. Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants. HIV Clinical Trials 2006;7:70-85.
• Liu H, Dow EC, Arora R, Kimata JT, Bull LM, Arduino RC, and Rice AP. Integration of HIV-1 during untreated infection occurs preferentially within genes. Journal of Virology 2006;80:7765-8.
• Vidrine DJ, Arduino RC, Gritz ER.  Impact of a cell phone intervention on mediating mechanisms of smoking cessation in individuals living with HIV/AIDS. Nicotine Tob Res. 2006 Dec;8 Suppl 1:S103-8.
• The Strategies for Management of Anti-Retroviral Therapy (SMART) Study Group.  CD4+ Cell Count–Guided Antiretroviral Treatment.  N. Engl. J Med. 2006;355:2283-96.
• Torres JA, Barnett BJ, and Arduino RC.  Use of fosamprenavir, a sulfa-containing protease inhibitors, in HIV-infected patients with Glucose 6-Phosphate Dehydrogenase Deficiency.  Clinical Infectious Diseases.  2007;44:887-888.
• Lewis DE, Gross KL, Diez MM, Martinez ML, Lukefahr HN, Kozinetz CA, Arduino RC. CD8 apoptosis may be a predictor of T cell number normalization after immune reconstitution in HIV. J Transl Med. 2007 Jan 30;5(1):9.
• Vidrine DJ, Arduino RC, Gritz ER. The effects of smoking abstinence on symptom burden and quality of life among persons living with HIV/AIDS.  AIDS Patient Care STDs (in press).
• Torres HA, Bull L, Arduino RC, Barnett BJ. Tongue Hyperpigmentation in a Caucasian Patient Coinfected With HIV and Hepatitis C During Peginterferon Alfa-2b and Ribavirin Therapy. Am J Gastroenterol. 2007 Jun;102(6):1334-1335.
• Fingeret MC, Vidrine DJ, Arduino RC, Gritz ER. The association between body image and smoking cessation among individuals living with HIV/AIDS.  Body Image 4 (2007) 201–206.
• Torres HA, Bull L, Arduino RC. Fosamprenavir calcium plus ritonavir for HIV infection. Expert Rev Anti Infect Ther. 2007 Jun;5(3):349-63.
• Torres HA, Barnett BJ, Arduino RC. Alopecia associated with ritonavir-boosted atazanavir therapy. AIDS. 2007 Jun;21(10):1391-1392.

Professional Organizations:
• American Society for Microbiology
• American Academy of HIV Medicine
• Infectious Diseases Society of America

Lisa Y. Armitige, MD, PhD
Assistant Professor of Medicine

Lisa Y. Armitige, MD, PhD Assistant Professor of Medicine Lisa Y. Armitige, MD, PhD graduated from Rice University, received her MD from the University of Texas Medical School at Houston in 1998 and her PhD in 2002 from the University of Texas Graduate School of Biomedical Sciences. She did a Med/Peds residency at UT Houston from 1998-2002. She was on the faculty in general internal medicine until 2003, when she did her ID fellowship at UT Medical School, Houston from 2003-2005. Her research interest is pathogenesis of Mycobacterium tuberculosis. Current studies in her laboratory include investigations of M. tuberculosis virulence factors and correlates of the bacteria’s behavior with human host response.

Peer Reviewed Publications since 2000:

• Armitige LY, Jagannath C, Wanger AR, and Norris SJ. 2000. Disruption of the genes encoding Antigen 85A and Antigen 85B of Mycobacterium tuberculosis H37Rv: Effect on growth in culture and in macrophages. Infect Immun. 68:767-778.
• Puech V, Guilhot C, Perez E, Tropis M, Armitige LY, Gicquel B, Daffe M. 2002. Evidence for a partial redundancy of the fibronectin-binding proteins for the transfer of mycoloyl residues onto the cell wall arabinogalactan termini of Mycobacterium tuberculosis. Mol Microbiol. 44(4):1109-22.
• Smith K, Armitige LY, Wanger AR. 2003. A review of tuberculosis: reflections on the past, present and future of a global epidemic disease. Expert Rev. Anti-infect. Ther. 1(3), 483-491
• Copenhaver RH, Sepulveda E, Armitige LY , Actor JK, Wanger A, Norris SJ, Hunter, Jr RL, Jagannath C. 2004. A mutant of Mycobacterium tuberculosis H37Rv that lacks the expression of Antigen 85A is attenuated in mice but retains a vaccinogenic potential. Infect Immun. 72(12), 7084-95.
• Singh CR, Moulton RA, Armitige LY, Bidani A, Snuggs M, Dhandayuthapani S, Hunter RL and Jagannath C. 2006. Processing and presentation of a mycobacterial antigen 85B epitope by murine macrophages is denpendent on the phagosomal acquisition of vacuolar proton ATPase and in situ activation of cathepsin D. J Immunol. 177(5): 3250-9.
• Mohamed JA, DuPont HL, Jiang ZD, Belkind-Gerson J, Figueroa JF, Armitige LY, Tsai A, Nair P, Martinez-Sandoval FJ, Guo DC, Hayes P, Okhuysen PCO. 2007. A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infec Dis. 44(7)_945-52.

Professional Organizations:
• American Society for Microbiology
• Infectious Diseases Society of America
• American College of Physicians
• American Academy of Pediatrics

Ben J. Barnett, MD
Associate Professor of Medicine
Associate Medical Director, Harris County Hospital District HIV Services

Ben J. Barnett, MD received his medical degree (AOA) from The University of Texas Medical Branch at Galveston. He completed his residency and fellowship at Emory University in Atlanta, Georgia, and was an Epidemic Intelligence Service officer at CDC. Dr. Barnett is an Associate Professor, Department of Internal Medicine, and Division of Infectious Diseases at UT-Houston Medical School. He is Associate Medical Director of HIV Services for the Harris County Hospital District. He is board certified by the American Board of Internal Medicine in Internal Medicine and Infectious Diseases. In addition to being a consummate clinician and teacher, Dr. Barnett also conducts clinical research on HIV/AIDS.

As part of a study group:
• Lalezari JP, Henry K, O'Hearn M, et. al, for the TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
• Squires K, Pozniak AL, Pierone G Jr., et al, for the Gilead 907 Study Group. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139:313-20.
• Eron JJ, Gulick RM, Bartlett JA, et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis. 2004; 189(6):1075-83.
• Gallant JE, Staszewski S, Pozniak, et al. for the 903 study group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292(2):191-201.
• Gallant JE, DeJesus E, Arribas JR, et al. for the 934 study group. Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV. N Engl J Med. 2006;354:251-60.

Professional Organizations:
• American Academy of HIV Medicine
• American Society for Microbiology
• Society for Healthcare Epidemiology of America
• Infectious Diseases Society of America
• American College of Physicians, Fellow
• Texas Infectious Disease Society

Tanvir K. Bell, MD
Assistant Professor of Medicine

Tanvir Bell, MD received her medical degree from UMNDJ—Robert Wood Johnson Medical School in 1995. She did her Internal Medicine residency at the University of Pittsburgh Medical Center in Pittsburgh, PA and her Infectious Diseases fellowship at Case Western Reserve University in Cleveland, OH. She has been the director of HIV clinics at Allegheny General Hospital in Pittsburgh, PA and University of Texas Medical Branch in Galveston, TX prior to her arrival here in October 2005. She participates in HIV/AIDS clinical trials and a Clostridium difficile clinical trial.  She has an interest in issues with HIV infected women and  cardiovascular  complications of HIV disease.

Peer reviewed publications since 2000:

• Donsky CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, Hutton-Thomas RA, Whalen CC, Bonomo RA, Rice LB. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. New England Journal of Medicine 2000; 343(26): 1925-32.
• Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, Davidson R, Beinker N, Gripshover BM, Salata RA, McComsey G, Weissman SB, Lederman M. The Changing Spectrum of HIV Mortality: Analysis of 260 Deaths from 1995-1999. Clinical Infectious Diseases 2001; 32: 1487-93.
• Beinker N, Mayers DL, Lange CG, Valdez H, Sitkins J, Lemonnier L, Chowdhry TK, Lederman MM. Brief Report: Genotypic drug resistance and cause of death in HIV-infected persons who died during 1999. Journal of Acquired Immune Deficiency Syndromes 2001; 28(3): 250-53.

Professional Organizations:
• HIV Medicine Association
• American Society for Microbiology
• Infectious Diseases Society of America

Agathe Bourgogne, PhD
Instructor in Medicine, Research

Agathe Bourgogne, PhD received her PhD in Microbiology and Molecular Biology from Université Aix-Marseille II. She is a co-investigator in Dr. Murray’s laboratory. Before joining Dr. Murray’s laboratory she worked on pathogenesis of Bacillus anthracis.

Peer reviewed publications since 2000:
• Bourgogne A, Drysdale M, Hilsenbeck SG, Peterson SN, Koehler TM. Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun. 2003 May;71(5):2736-43
• Drysdale M, Bourgogne A, Hilsenbeck SG, Koehler TM. atxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB. J Bacteriol. 2004 Jan;186(2):307-15.
• Tinsley E, Naqvi A, Bourgogne A, Koehler TM, Khan SA. Isolation of a minireplicon of the virulence plasmid pXO2 of Bacillus anthracis and characterization of the plasmid-encoded RepS replication protein. J Bacteriol. 2004 May;186(9):2717-23.
• Drysdale M, Bourgogne A, Koehler TM. Transcriptional analysis of the Bacillus anthracis capsule regulators. J Bacteriol. 2005 Aug;187(15):5108-14.
• Bourgogne A, Hilsenbeck SG, Dunny GM, Murray BE. Comparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: the Fsr system of Enterococcus faecalis is more than the activator of gelatinase and serine protease. J Bacteriol 2006; 188:2875-2884.
• Bourgogne A, Singh KV, Fox KA, Pflughoeft KJ, Murray BE, Garsin DA: EbpR is important for biofilm formation by activating expression of the endocarditis and biofilm-associated pilus operon (ebpABC) of Enterococcus faecalis OG1RF. J Bacteriol 2007, 189(17):6490-6493.

Professional Organizations:
• American Society for Microbiology

Herbert L. Dupont, MD
Mary W. Kelsey Professor of the Medical Sciences, The University of Texas-Houston Medical School
Chief, Internal Medicine Service, St. Luke's Episcopal Hospital Director, Center for Infectious Diseases, Professor of Epidemiology, The University of Texas-Houston School of Public Health
Clinical Professor, The University of Texas-Houston Medical School
H. Irving Schweppe, Jr., M.D. Chair in Internal Medicine and Vice Chairman, Department of Medicine, Baylor College of Medicine
Clinical Professor, Department of Medicine and Adjunct Professor, Department of Microbiology and Immunology, Baylor College of Medicine
Faculty Member, Graduate Schools of Biomedical Sciences, University of Texas – Houston and Baylor College of Medicine
E-mail: Herbert.l.dupont@uth.tmc.edu

Herbert L. DuPont, MD received his medical degree from Emery University in 1965 and did his internal medicine residency at the University of Minnesota Hospitals followed by an ID fellowship at University of Maryland from 1967-1969, when he was also an EIS officer for the CDC. Dr. DuPont rose rapidly through the ranks. He was appointed Professor of Medicine and Chair of Infectious Diseases and Clinical Microbiology at the University of Texas Medical School at Houston in 1973. He became chief of the internal medicine service at St. Luke’s Episcopal Hospital in 1995. He has been director of the Center for Infectious Diseases at the UT School of Public Health since 2000. The major focus of Dr. DuPont's research has been to couple laboratory research techniques with application to population studies in the field to study acute infectious diarrhea. Most studies have taken place in countries outside the United States: Mexico, Peru, Egypt, Jamaica, Zambia, Thailand, Kenya and India. A volunteer program was established in Houston to study enteric infectious diseases in humans where the emphasis or research direction has dealt with immunology and pathogenesis of disease. Major foci of the international studies have been on the epidemiology, immunology, clinical features, control, prevention and therapy of selected diarrheal diseases with public health implications. The approaches taken are practical and have clinical applicability. Basic science projects are performed as needed to help fully develop the larger questions suggested by field and laboratory research. Major current interests include studies of the pathogenesis and etiology of travelers’ diarrhea, Clostridium difficile diarrhea and colitis and post-infectious irritable bowel syndrome.

Peer reviewed publications since 2000.

Charles D. Ericsson, MD
Professor of Medicine
Head, Clinical Infectious Diseases
Vice Director, Infectious Disease Fellowship Program
Director, Travel Medicine Clinic
Administrative Director, Clinical Infectious Diseases Elective 4th year students
Co-Director, 3rd-4th Year Medical Student Affairs in Medicine

Charles D. Ericsson, MD received his medical degree from Harvard Medical School in Boston, Massachusetts. After residency training at the University of Minnesota hospitals, he completed a fellowship in infectious diseases at UT- Medical School at Houston. Dr. Ericsson is a Professor of Medicine at UT-Houston Medical School and Head, Clinical Infectious Diseases, Department of Internal Medicine, Director of the Travel Medicine Clinic and Vice Director of the Infectious Diseases Fellowship program at UT Medical School at Houston. He is board certified by the American Board of Internal Medicine. Dr. Ericsson has heavy clinical infectious diseases consultative and teaching duties. He has received several awards for his teaching. He is founding Editor-in-Chief of The Journal of Travel Medicine and Past President of the International Society of Travel Medicine. He is also Travel Medicine Section Editor of Clinical Infectious Diseases. His current research interests include travelers’ diarrhea and travel medicine; he has journeyed each summer to Guadalajara Mexico to conduct clinical trials in travelers’ diarrhea since 1975. He is also heavily involved in hospital infection control and antibiotic approval programs. .

Peer reviewed publications since 2000.

• Sutjita M, Bouckenooge A, Adachi JA, Jiang Z-D, Ericsson CD, DuPont HL. Intestinal secretory IgA response to enteroaggregative Escherichia coli in travelers. Clin Diag Lab Immunol 7:501-3, 2000.
• Adachi JA, D'Alessio FR, Ericsson CD. Reactive arthritis associated with typhoid vaccination in travelers: report of two cases with negative HLA-B27. J Travel Med. 7:35-6, 2000.
• Jiang Z-D, Mathewson JJ, Ericsson CD, Svennerholm A-M, Pulido C, DuPont HL. Characterization of enterotoxigenic Escherichia coli (ETEC) strains in patients with travelers’ diarrhea acquired in Guadalajara, Mexico, 1992 through 1997. J Infect Dis 181:779-82, 2000.
• Adachi J, Ostrosky-Zeichner L, DuPont HL, Ericsson CD. Empirical antimicrobial therapy for travelers’ diarrhea. Clin Infec Dis 31:1079-83, 2000.
• Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infec Dis. 33, 375-379, 2001
• DuPont HL, Jiang Z-D, Ericsson CD, Adachi JA, Mathewson JJ, DuPont MW, Palazzini E, Riopel LM, Ashley D, Martinez-Sandoval F. Rifaximin versus ciprofloxacin for the treatment of travelers’ diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 33:1807-15, 2001
• Adachi JA, Jiang, Z-D, Mathewson JJ, Mangala P, Verenkar MP, Thompson S, Martinez-Sandoval F, Steffen R, Ericsson CD, DuPont HL. Enteroaggregative Escherichia coli as a major etiologic agent in travelers’ diarrhea in three regions of the world. Clin Infect Dis 32:1706-9, 2001
• Ericsson CD, DuPont HL, Mathewson JJ: Optimal dosing of ofloxacin with loperamide in the treatment of non-dysenteric travelers’ diarrhea. J Travel Med 8:19-25, 2001
• De La Rosa GR, Barnett BJ, Ericsson CD, Turk JB. Native valve endocarditis due to Bartonella henselae in a middle-aged Human Immunodeficiency Virus-negative woman. J Clin Microbiol 39:3417-19, 2001.
• Huang DB, Jiang ZD, Ericsson CD, Adachi J, Dupont HL. Emergence of trimethoprim-resistant Escherichia coli in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico. Scand J Infect Dis 33:812-4, 2001.
• Adachi JA, Mathewson JJ, Jiang ZD, Ericsson CD, Dupont HL. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico and Houston, Texas. Ann Intern Med 136:884—887, 2002.
• Bouckenooghe AR, Jiang ZD, De La Cabada FJ, Ericsson CD, DuPont HL. Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico. J Travel Med 9:137-40, 2002.
• Adachi JA, Ericsson CD, Jiang ZD, DuPont MW, Pallegar SR, DuPont HL. Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico. J Infect Dis 185:1681-3, 2002.
• Marcolini J, Nguyen M, Ericsson CD. Klebsiella pneumoniae brain abscess in a Taiwanese adult. J Infect 44: 205-206, 2002;
• Ericsson, CD. Travelers with pre-existing medical conditions. International J Antimicrob Agents 2003; 21: 181-88.
• Ericsson, CD. Travelers’ diarrhea. International J Antimicrob Agents 2003; 21: 116-24.
• Steffen, R, Sack, DA, Riopel, L, Jiang Z-D, Stürchler, M, Ericsson, CD, Lowe, B, Waiyaki, P, White, M, DuPont, HL. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003: 98:1073-78.
• Adachi, JA, Ericsson, CD, Jiang, Z-D, DuPont, MW, Martinez-Sandoval, F, Knirsch, C, DuPont, HL. Azithromycin is Comparable to Levofloxacin in the Treatment of U.S. Travelers with Acute Diarrhea Acquired in Mexico. CID 37:1165-71, 2003
• Infante RM, , Ericsson CD, Jiang Z-D, Ke S, Steffen R, Riopel L, Sack DA, DuPont HL. Enteroaggregative Escherichia coli (EAEC) Diarrhea in Travelers: Response to Rifaximin Therapy. Clin Gastroenterol Hepatology 2004; 2:135-8.
• Huang DB, Sanchez AP, Triana E, Jiang Z-D, DuPont HL, Ericsson CD. US male students who heavily consume alcohol in Mexico are at greater risk of travelers’ diarrhea than their female counterparts. J Travel Med 2004; 11:143-147.
• Huang DB, Awasthi M, Le J, Leve M, DuPont MW, DuPont HL, Ericsson CD. The role of diet in the treatment of travelers’ diarrhea: a pilot study. CID 2004; 39:468-71.
• Mohr JF, Ericsson CD, Hall AC, Ostrosky-Zeichner L. Amphotericin B Overdose: A Fatal Case of Lipid and Non-Lipid Formulation Mix-Up. Pharmacotherapy 2005; 25: 426-8.
• Ericsson CD, DuPont HL. Rifaximin in the treatment of infectious diarrhea. Chemother 2005; 51(suppl 1):73-80.
• DuPont HL, Jiang Z-D, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. Prevention of travelers’ diarrhea with rifaximin, a non-absorbed antibiotic. Annals Intern Med 2005; 142: 805-12.
• DuPont HL, Jiang Z-D, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. Antibacterial chemoprophylaxis in the prevention of travelers’ diarrhea. Clin Infect Dis 2005; 41:S
• Ericsson CD. Non antimicrobial agents in treatment and prevention of travelers’ diarrhea. Clin Infec Dis 2005; 41:S557-63.
• Ericsson CD. Safety and tolerability of the antibacterial rifaximin in the treatment of travelers’ diarrhea. Drug Safety 2006; 29:201-7.
• Taylor DN, Bourgeois AL, Ericsson CD, Steffen R, Jiang Z-D, Halpern J, Haake R, Kamm AR, DuPont HL and the Rifaximin Study Group. A Randomized, Double-Blind, Multicenter Study of Rifaximin Compared with Placebo and with Ciprofloxacin in the Treatment of Travelers’ Diarrhea. (Am J Trop Med Hygiene 2006; 74:1060-66.
• Hill DR, Ericsson CD, Pearson RD, Keystone JS, Freedman DO, Kozarsky PE, DuPont HL, Bia FJ, Fischer PR, Ryan ET.  Guidelines for the Practice of Travel Medicine.  Clin Infec Dis 2006; 43:1499-1539.
• DuPont HL, Haake R, Taylor DN, Ericsson CD, Jiang Z-D, Okhuysen P, Steffen R. Rifaximin treatment of pathogen-negative travelers’ diarrhea.  J Travel Med 2007; 14:16-19.
• Dupont HL, Jiang ZD, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, Dupont MW, Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez Sandoval F. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007; 5:451-6
• Ericsson CD, DuPont HL, Okhuysen PC, Jiang Z-D, de la Cabada FJ, DuPont MW, Martinez-Sandoval F. Loperamide plus azithromycin more effectively treats travelers’ diarrhea in Mexico than azithromycin alone. J Travel Med 2007; 14:312-319.
• Meraz IM, Jiang Z-D, Bourgeois AL, Steffen R, Ajami NJ, Koo HL, Ericsson CD, Taylor DN, DuPont HL.  Etiology of pathogen negative travelers’ diarrhea - a PCR-based study of selected enteropathogens.  (in preparation)

Professional Organizations:

• American College of Physicians, Fellow
• American Society for Microbiology
• American Society of Tropical Medicine and Hygiene
• Infectious Diseases Society of America, Fellow
• International Society of Travel Medicine,
Past President
Founding Editor, Journal of Travel Medicine
• Wilderness Medicine Society
• Houston Infectious Diseases Society

Sreedhar R. Nallapareddy, PhD
Assistant Professor, Internal Medicine Research

Sreedhar R. Nallapareddy, PhD received a PhD in genetics in 1998 from the University of Madras, Madras, India. Dr. Nallapareddy is co-investigator in Dr. Murray’s laboratory.

Peer reviewed publications since 2000:
• Nallapareddy, S.R., Singh, K.V., Duh, R.W., Weinstock, G.M., and Murray, B.E.: Diversity of ace, a gene encoding a microbial surface component recognizing adhesive matrix molecules, from different strains of Enterococcus faecalis and evidence for production of ace during human infections. Infect Immun. 68:5210-5217, 2000
• Nallapareddy, S.R., Qin, X., Weinstock, G.M., Hook, M., and Murray, B.E.: An Enterococcus faecalis OG1RF adhesin, Ace, mediate attachment to extracellular matrix proteins collagen type IV and laminin as well as collagen type I. Infect Immun. 68:5218-5224, 2000.
• Nallapareddy, S.R., Duh, R.W., Singh, K.V., and Murray, B.E.: Molecular typing of selected Enterococcus faecalis isolates: Pilot study using multilocus sequence typing and pulsed-field gel electrophoresis. J Clin Microbiol. 40: 868-876. 2002.
• Gilmore, M.S., Coburn, P.S., Nallapareddy, S.R., and Murray, B.E.: Enterococcal Virulence. In: The Enterococci: Pathogenesis, Molecular Biology and Antibiotic Resistance, Eds. M. S. Gilmore, D. Clewell, P. Courvalin, G. M. Dunny, B. E .Murray, and L. Rice. ASM Press, Washington, DC, 2002.
• Hubble, T.S., Hatton, J.F., Nallapareddy, S.R., Murray, B.E., and Gillespie, M.J.: Influence of Enterococcus faecalis proteases and the collagen-binding protein, Ace, on adhesion to dentin. Oral Microbiol and Immunol.18:121-126, 2003.
• Nallapareddy, S.R., Weinstock, G.M., and Murray, B.E.: Clinical isolates of Enterococcus faecium exhibit strain-specific collagen binding mediated by Acm, a new member of the MSCRAMM family. Mol Microbiol. 47:1733-1747. 2003.
• Nallapareddy, S.R., Wenxiang, H., Weinstock, G.M., and Murray, B.E.: Molecular characterization of a widespread, pathogenic, and antibiotic resistance-receptive Enterococcus faecalis lineage and dissemination of its putative pathogenicity island. J Bacteriol. 187: 5709-5718. 2005.
• Rice, L.B., Carias, L., Rudin, S., Vael, C., Goossens, H., Konstabel, C., Klare, I., Nallapareddy, S.R., Huang, W., and Murray, B.E.: A potential virulence gene, hylEfm, predominates in Enterococcus faecium of clinical origin. J Infect Dis. 187:508-512, 2003.
• Sillanpaa, J., Xu, Y., Nallapareddy, S.R., Murray, B.E., and Hook, M.: A family of putative MSCRAMMs from Enterococcus faecalis. Microbiology. 150:2069-2078, 2004.
• Mohamed, J. A., Huang, W., Nallapareddy, S.R., Teng, F., Murray B.E.: Influence of origin of isolates, especially endocarditis isolates, and various genes on biofilm formation by Enterococcus faecalis. Infection and Immunity 72:3658-63, 2004.
• Mohamed, J.A., Teng, F., Nallapareddy S.R., Murray, B.E.: Pleiotrophic effects of 2 Enterococcus faecalis sagA-like genes, salA and salB, which encode proteins that are antigenic during human infection, on biofilm formation and binding to collagen type I and fibronectin. J Infect Dis 193:231-240, 2006
• Nallapareddy, S.R., Singh, K.V., and Murray. B.E: Construction of improved temperature-sensitive and mobilizable vectors and their use for constructing mutations in the adhesin encoding acm gene of poorly transformable clinical Enterococcus faecium Strains. Appl Environ Microbiol. 72:334-345, 2006
• Singh K.V., Nallapareddy, S.R., Nannini E.C., and Murray B.E.: Fsr-independent production of protease(s) may explain the lack of attenuation of an Enterococcus faecalis fsr mutant versus a gelE-sprE mutant in induction of endocarditis. Infect Immun. 73:4888-4894, 2005.
• Kowalski, W.J., Kasper, E.L., Hatton, J.F., Murray, B.E., Nallapareddy, S.R., and Gillespie, M.J.: Enterococcus faecalis adhesin, ace, mediates attachment to particulate dentin. J Endod 32:634-637, 2006.
• Ruiz-Garbajosa, P., Bonten, M.J., Robinson, D.A., Top, J., Nallapareddy, S.R., Torres, C., Coque, T.M., Canton, R., Baquero, F., Murray, B.E., et al.: Multilocus sequence typing scheme for Enterococcus faecalis reveals hospital-adapted genetic complexes in a background of high rates of recombination. J Clin Microbiol 44:2220-2228,2006
•Nallapareddy, S.R., and Murray, B.E.: Ligand-Signaled Upregulation of Enterococcus faecalis ace Transcription, a Mechanism for Modulating Host-E. faecalis Interaction. Infect Immun, 74:4982-89, 2006.
• Nallapareddy, S.R., Singh, K.V., Sillanpaa, J., Garsin, D.A., Hook, M., Erlandsen, S.L., and Murray, B.E.: Endocarditis and biofilm-associated pili of Enterococcus faecalis. J Clin Invest 116:2799-807, 2006.
• Nallapareddy, S.R., Sillanpaa, J., Ganesh, V.K., Hook, M., and Murray B.E.: Inhibition of Enterococcus faecium adherence to collagen by antibodies against high-affinity binding subdomains of Acm. Infect Immun 75:3192-6, 2007.
• Singh, K.V., Nallapareddy, S.R., and Murray B.E.: Importance of the ebp (endocarditis- and biofilm-associated pilus) locus in the pathogenesis of Enterococcus faecalis ascending urinary tract infection. J Infect Dis 195:1671-7, 2007.
• Kemp, K.D., Singh, K.V., Nallapareddy, S.R., and Murray B.E.: Relative contributions of Enterococcus faecalis OG1RF sortase-encoding genes, srtA and bps (srtC), to biofilm formation and a murine model of urinary tract infection. Infect Immun 75:5399-404, 2007.
• Nallapareddy, S.R., and Murray B.E.: Role of Serum, a biological cue, in adherence of Enterococcus faecalis to extracellular matrix proteins, collagen, fibrinogen, and fibronectin, J Infect Dis, In Press. 2008

Professional Organizations:
• American Society for Microbiology

Pablo C. Okhuysen, MD
Professor of Medicine
Director, Clinical Research Unit
Past Director, Infectious Disease Fellowship Program

Pablo C. Okhuysen, MD received his medical school training at the Universidad Autonoma de Guadalajara. He performed his internship at Cook County Hospital in Chicago and completed his residency at the University of Texas Medical School at Houston, where he stayed on to do a fellowship in infectious diseases and eventually joined the faculty. He quickly rose to the rank of Professor and has previously served as the Director of the ID fellowship program at UT Medical School.

His successful research program is NIH funded and focuses on HIV and enteric diseases. Dr. Okhuysen works on the pathogenicity, epidemiology and host response to Cryptosporidium parvum. In a related project he aims to identify host genetic polymorphisms that are associated with susceptibility to agents of infectious diarrhea, emphasizing infections due to Enterotoxigenic E. coli, enteroaggregative E. coli and Cryptosporidium. He is now Director of the Clinical Research Unit and is co-Director of the Center for Clinical and Translational Sciences. The goals of the CRU are to provide an environment for the study of normal and abnormal body function; investigate the cause, progression, prevention, control and care of human disease; furnish an optimal setting for controlled clinical investigations by UTHSC scientists and serve as an environment for training health professionals in clinical research.

Dr. Okhuysen is principal investigator for the UTHSC component of the NIH funded vaccine trials and evaluation unit (VTEU) at Baylor College of Medicine. VTEU related studies include volunteer challenge studies with enteroaggregative E. coli and seroepidemiologic studies on Enterotoxigenic E. coli.

Selected Peer Reviewed Publications since 2000:

• White AC, Robinson P, Okhuysen PC, Lewis DE, Shahab I, Lahoti S, DuPont HL, Chappell CL. Interferon-gamma Expression in jejunal biopsies in experimental human cryptosporidiosis correlates with prior sensitization and control of oocyst excretion. J Infect Dis. 2000 Feb; 181(2): 701-709.
• Robinson P, Okhuysen PC, Chappell CL, Lewis DE, Shahab I, Lahoti S, White, Jr., AC.TGF-?1 is expressed in the jejunum after experimental human Cryptosporidium parvum infection. Infect Immun.2000;68: 5405-5407.
• Dann MS, Okhuysen PC, DuPont HL, Chappell CL, Fecal antibody response to Cryptosporidium parvum in healthy volunteers. Infect and Immun. 2000;68:5068-5074.
• Robinson P, Okhuysen PC, Chappell CL., Lewis DE., Shahab I, Janecki A, White, AC, Jr. Expression of tumor necrosis factor alpha and interleukin ß1in jejuna of volunteers after experimental challenge with Cryptosporidium parvum correlates with exposure but not with symptoms. Infect. Immun. 2001 69: 1172-1174.
• Okhuysen PC, Robinson P, Nguyen MT, Nannini E, Lewis D, Lahoti S, Chappell C, White, AC. The jejunal cytokine response in patients with AIDS associated cryptosporidiosis during immune reconstitution. AIDS, 15:802-804, 2001.
• Okhuysen PC. Traveler’s Diarrhea due to Intestinal Protozoa. Clin Inf Dis . 33:110-114, 2001.
• Robinson, P, Okhuysen PC, Chappell, CL, Lewis DE, Shahab I, Lahoti S, and White AC Jr. Expression of IL-15 and IL4 in INF-?-Independent control of experimental human Cryptosporidium parvum Infection. Cytokine 7:39-46, 2001.
• Padda R, Tsai A, Chappell, CL, Okhuysen PC. Molecular cloning and analysis of the Crytosporidium pavum aminopeptidase N Gene. Int. J. Parasitol. 2002, 32:187-197.
• Okhuysen, PC, CL Chappell, Cryptosporidium virulence determinants – are we there yet? Int. J. Parasitol. 32:517-525, 2002.
• Okhuysen, PC, Rich SM, Chappell CL, Grimes KA, Widmer G, Feng X, Tzipori S. Infectivity of a Cryptosporidium parvum isolate of cervine origin for healthy adults and gamma Interferon-? knock out mce. J. Infect Dis. 2002, 185:1320-1325.
• Teunis PF, Chappell CL and Okhuysen PC. Cryptosporidium dose-response studies: variation between hosts. Risk Analysis. 2002:3, 475-485.
• Teunis PF, Chappell CL Okhuysen PC. Cryptosporidium dose response studies: variation between isolates. Risk Analysis. 2002:1, 175-183.
• Millership JJ, Chappell C, Okhuysen PC, Snowden KF.Characterization of aminopeptidase activity from three species of microsporidia: Encephalitozoon cuniculi, Encephalitozoon hellem,and Vittaforma corneae. J Parasitol. 2002:88:843-8
• Nannini EC, Okhuysen PC. HIV1 and the gut in the era of highly active antiretroviral therapy. Curr. Gastroenteral Rep. 2002, 4:392-298.
• Alcantara CA, Steiner T, Barret L, Guerrant RL, Yang CH, Lima A, Chappell CL, Okhuysen PC, White AC. IL-8, TNF-alpha and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis. Am J Trop Med Hyg. 2003:3; 325-328.
• Jiang ZD, Okhuysen PC, Guo DC, He R, King TM, DuPont HL, Milewicz DM. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis 2003;188:506-11.
• Robinson P, Okhuysen PC, Chappell CL, Weinstock JV, Lewis DE, Actor JK, White AC, Jr. Substance P expression correlates with severity of diarrhea in cryptosporidiosis. J Infect Dis 2003;188:290-6.
• White AC, Jr., Robinson P, Okhuysen PC. Human studies provide insight into the pathogenesis, immunology, and treatment of cryptosporidiosis. Clin Infect Dis 2003;37:989; author reply 989-90.
• Huang DB, Okhuysen PC, Jiang ZD, DuPont HL. Enteroaggregative Escherichia coli: an emerging enteric pathogen. Am J Gastroenterol 2004;99:383-9.
• Okhuysen PC, Rogers GA, Crisanti A, Spano F, Huang DB, Chappell CL, Tzipori S. Antibody response of healthy adults to recombinant thrombospondin-related adhesive protein of Cryptosporidium 1 after experimental exposure to Cryptosporidium oocysts. Clin Diagn Lab Immunol 2004;11:235-8.
• Roberts JC, Singh KV, Okhuysen PC, Murray BE. Molecular epidemiology of the fsr locus and of gelatinase production among different subsets of Enterococcus faecalis isolates. J Clin Microbiol 2004;42:2317-20.
• Huang DB, DuPont HL, Jiang ZD, Carlin L, Okhuysen PC. Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic Escherichia coli. Clin Diagn Lab Immunol 2004;11:548-51.
• Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J. Gastroenterol. 2004 99:1774-8.
• Kjos SA, Jenkins M, Okhuysen PC, Chappell CL. Evaluation of Recombinant Oocyst Protein CP41 for Detection of Cryptosporidium-Specific Antibodies. Clin Diagn Lab Immunol. 2005;12:268-72.
• Huang DB, Chappell C, Okhuysen PC. Cryptosporidiosis in children. Semin Pediatr Infect Dis. 2004 15(4):253-9.
• Kjos SA, Jenkins M, Okhuysen PC, Chappell CL. Evaluation of Recombinant Oocyst Protein CP41 for Detection of Cryptosporidium-Specific Antibodies.Clin Diagn Lab Immunol. 2005. 12:268-72.
• DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-812.
• Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E and Okhuysen PC. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25:1303-9
• Okhuysen PC, Chappell CL, Lewis DE, Robinson P and White AC, Jr. Treatment of chronic cryptosporidiosis in AIDS with rIL-12 induces an immune response associated with improvement but severe side-effects. AIDS 2005;19:1333-4.
• Ko G, Garcia C, Jiang ZD, Okhuysen PC, Belkind-Gerson J, Glass RI, DuPont HL. Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. J Clin Microbiol. 2005;43:6126-9.
• Ko G, Jiang ZD, Okhuysen PC, Dupont HL. Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to Noroviruses. J Med Virol 2006;78:825-8.
• Jiang ZD, Dupont HL, Garey K, Price, M, Graham, G, Okhuysen, P, Dao-Tran, T, Larocco, M. A Common Polymorphism in the Interleukin 8 Gene Promoter Is Associated with Clostridium difficile Diarrhea. Am J Gastroenterol 2006:101;1112-1116
• Huang DB, Mohanty A, Dupont HL, Okhuysen PC, Chiang T. A review of an emerging enteric pathogen: enteroaggregative Escherichia coli. J Med Microbiol. 2006;55:1303-11.
• Huang DB, Nataro JP, DuPont HL, Kamat PP, Mhatre AD, Okhuysen PC, Chiang T. Enteroaggregative Escherichia coli is a cause of acute diarrheal illness: a meta-analysis. Clin Infect Dis. 2006;43:556-63.
• Chappell CL, Okhuysen PC, Langer-Curry R, et al. Cryptosporidium hominis: experimental challenge of healthy adults. Am J Trop Med Hyg 2006;75:851-7
• The strategies for Management of Antiretroviral Therapy (SMART) Study Group.  CD4+ Count-Guided Interruption of Antiretroviral Treatment.  N. Engl J Med 2006:355;2283-96
• Wang HC, Dann SM, Okhuysen PC, Lewis DE, Chappell CL, Adler DG, White AC, Jr. High levels of CXCL10 are produced by intestinal epithelial cells in AIDS patients with active cryptosporidiosis but not after reconstitution of immunity. Infect Immun. 2007;75:481-7.
• Mohamed JA, Huang DB, Jiang ZD, Dupont HL, Nataro JP, Belkind-Gerson J, Okhuysen PC. Association of putative enteroaggregative Escherichia coli virulence genes and biofilm production in isolates from travelers to developing countries. J Clin Microbiol. 2007;45:121-126.
• Mohamed JA, Dupont HL, Jiang ZD, Belkind-Gerson J, Flores-Figueroa JF, Armitige LY, Nair P, Tsai A, Martinez-Sandoval FJ, Guo DC, Okhuysen PC A novel single nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infect Dis. 2007:44:945-52
• Aguirre-Garcia MM, Okhuysen PC Cryptosporidium parvum: identification and characterization of an acid phosphatase. Parasitol Res. 2007 101;85-9
• DuPont HL, Haake R, Taylor DN, Ericsson CD, Jiang ZD, Okhuysen PC, Steffen R. Rifaximin treatment of pathogen-negative travelers' diarrhea. J Travel Med. Jan-Feb 2007;14:16-9.
• The ESPRIT Research Group.  Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>/=300 cells/muL who were assigned to 7.5 MIU interleukin-2. HIV Med. 2007:8:112-23
• Dupont HL, Jiang ZD, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, Dupont MW, Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez Sandoval F.  Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol. 2007:5:451-6.
• Jiang ZD, Garey KW, Price M, Graham G, Okhuysen P, Dao-Tran T, Larocco M, Dupont HL. Association of Interleukin-8 Polymorphism and Immunoglobulin G Anti-Toxin A in Patients with Clostridium difficile-Associated Diarrhea, Clin Gastroenterol Hepatol. 2007;5:964-8
• Ericsson CD, DuPont HL, Okhuysen PC, Jiang ZD, DuPont MW. Loperamide Plus Azithromycin More Effectively Treats Travelers’ Diarrhea in Mexico than Azithromycin Alone.  J Travel Med. 2007 14;312–319
• Huang DB, Mohamed JA, Nataro JP, DuPont HL, Jiang ZD, Okhuysen PC. Virulence Characteristics and the Molecular Epidemiology of Enteroaggregative Escherichia coli Isolates from Travelers to Developing Countries. J Medical Microbiology 2007; 56: 1386-92.
• Flores J, DuPont HL, Jiang ZD, Belkind-Gerson J, Mohamed JA, Carlin LG, Padda R, Paredes, Martinez-Sandoval F, Villa NA, Okhuysen PC. Enterotoxigenic Escherichia coli Heat-Labile Toxin Seroconversion in US travelers to Mexico. Journal of Travel Medicine 2007; (In press).

Professional Organizations:
• AOA Medical Honors Society
• Houston Chapter American College of Physicians, Fellow
• American Society for Microbiology
• American Society of Tropical Medicine and Hygiene
• Infectious Diseases Society of America, Fellow
• Houston Infectious Diseases Society, president 08-09

Luis Ostrosky-Zeichner, M.D., FACP, FIDSA
Associate Professor of Medicine
Associate Director, Infectious Diseases Fellowship
Director, Laboratory of Mycology Research
Medical Director for Epidemiology, Memorial Hermann Hospital Texas Medical Center

Dr. Ostrosky-Zeichner obtained his medical degree from Universidad Nacional Autonoma de Mexico. He completed his internal medicine residency at Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, and his infectious diseases fellowship at the University of Texas Medical School at Houston and MD Anderson Cancer Center combined fellowship program. He has advanced training and experience in medical mycology and hospital epidemiology.

He is currently an associate professor of medicine and epidemiology, and the director of the Laboratory of Mycology Research, at the Division of Infectious Diseases of the University of Texas Medical School at Houston. He also serves as the associate fellowship program director and medical director for epidemiology for Memorial Hermann Texas Medical Center. He is a fellow of the American College of Physicians and the Infectious Diseases Society of America. He is an editorial board member of prestigious scientific journals such as Antimicrobial Agents and Chemotherapy, Critical Care Medicine, and Journal of Clinical Microbiology.

Dr. Ostrosky-Zeichner actively pursues translational and clinical research in medical mycology and hospital epidemiology, having over 100 publications in both fields. His areas of expertise include: antifungal susceptibility testing, fungal serologies, PK/PD of antifungals, in vivo models of human mycoses, immunology, and clinical trials in prophylaxis and treatment of fungal infections, as well as hospital epidemiology and infection control.

Key publications:

Professional Organizations:

Kavindra Vikram Singh, Ph.D.
Assistant Professor Internal Medicine Research

Kavindra Vikram Singh, Ph.D. received his PhD in 1981 from Sagar University, Sagar, India. He is a co-investigator in Dr. Murray’s laboratory. He is involved in teaching to graduate students and post doctoral M.D. fellows.

Peer reviewed publications since 2000:

Professional Orga